Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Global X Robotics and Artificial Intelligence ETF (BOTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Global X Robotics and Artificial Intelligence ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $280 (market cap $39.89B), while Global X Robotics and Artificial Intelligence ETF trades at $36.2. The key difference: Global X Robotics and Artificial Intelligence ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | BOTZ | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | — |
52-Week High | $491.22 | $41.63 |
52-Week Low | $278.09 | $31.99 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
BOTZ trades at $36.91, up 0.76% today, but faces a bearish technical outlook with moving averages signaling strong selling pressure. The robotics and AI ETF benefits from growing investor interest in physical AI applications, with recent news highlighting humanoid robotics as the next trillion-dollar opportunity. However, key financial ratios remain unavailable for analysis.
The ETF's outlook is supported by accelerating robotics adoption but challenged by technical weakness. Investment opportunity lies in the structural shift toward automation, while risks include market volatility and concentrated sector exposure. The neutral oscillator readings suggest potential for near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Global X Robotics and Artificial Intelligence ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →
